


PHARMACEUTICAL 2018



CytomX Therapeutics Inc. Rank 99 of 349





PHARMACEUTICAL 2018

CytomX Therapeutics Inc. Rank 99 of 349



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 120% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 250% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	388,601
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	61,147
Liabilities, Non-Current	1,897
Other Assets	3,876
Other Compr. Net Income	-67
Other Expenses	-513
Other Liabilities	264,704
Other Net Income	2,647
Property and Equipment	4,218
Research and Development	92,277
Revenues	71,623
Selling, General and Administrative Expense	25,605

Output Variable	Value in 1000 USD
Assets	397,644
Liabilities	327,748
Expenses	117,369
Stockholders Equity	69,896
Net Income	-43,099
Comprehensive Net Income	-43,132
Economic Capital Ratio	-27%